FOXO3 Longevity Genotype Mitigates Risk Posed by Hypertension on Incident Coronary Artery Disease in Middle-Aged Men: Kuakini Honolulu Heart Program
- PMID: 39497655
- PMCID: PMC11642614
- DOI: 10.1093/gerona/glae254
FOXO3 Longevity Genotype Mitigates Risk Posed by Hypertension on Incident Coronary Artery Disease in Middle-Aged Men: Kuakini Honolulu Heart Program
Abstract
Background: This study tested whether the carriage of the longevity-associated G-allele of FOXO3 SNP rs2802292 (TG/GG) protects against incident coronary artery disease (CAD) in men with hypertension.
Methods: Subjects were American men residing on Oahu having Japanese (n = 5415) or Okinawan (n = 897) ancestry and free of CAD at baseline (1965-1968) when aged 45-68 years.
Results: During the follow-up, there were 1 629 incident CAD cases. Adjusting for age and cardiovascular disease risk factors, the main effect Cox model showed that in men of Japanese ancestry, hypertension was a strong predictor of CAD (hazard ratio [HR] 1.61; 95% confidence interval [CI] 1.44-1.80), p < .0001), but TG/GG genotype was not associated with CAD (HR 0.92; 95% CI = 0.82-1.02; p = .11). A full Cox model showed the interaction of TG/GG with hypertension was significant (β = -0.23, p = .038). Stratified by hypertension status, TG/GG genotype TG/GG had a protective effect against CAD in each group (HR 0.83; 95% CI 0.71-0.96; p = .021 in men of Japanese heritage, and HR 0.66; 95% CI 0.43-1.01; p = .054 in men of Okinawan heritage). No association with CAD was seen in normotensive men having either Japanese (HR 1.04; 95% CI 0.89-1.22; p = .61) or Okinawan (HR 0.95; 95% CI 0.66-1.38; p = .79) heritage.
Conclusions: The present prospective study found that longevity-associated FOXO3 genotype did not independently affect the risk of CAD in all men. Rather, it was associated with protection against incident CAD in men with hypertension. Hypertensive middle-aged men with FOXO3TT genotype may merit particular attention in CAD prevention programs.
Keywords: FOXO3; Coronary artery disease; Genetics; Hypertension; Longevity.
© The Author(s) 2024. Published by Oxford University Press on behalf of The Gerontological Society of America.
Conflict of interest statement
None.
Figures
References
-
- Morris BJ, Willcox DC, Donlon TA, Willcox BJ.. FOXO3: a major gene for human longevity—a mini-review. Gerontology. 2015;61:515–525. https://doi.org/ 10.1159/000375235 - DOI - PMC - PubMed
-
- Bernardo VS, Torres FF, da Silva DGH.. FoxO3 and oxidative stress: a multifaceted role in cellular adaptation. J Mol Med. 2023;101:83–99. https://doi.org/ 10.1007/s00109-022-02281-5 - DOI - PubMed
-
- Abdellatif M, Rainer PP, Sedej S, Kroemer G.. Hallmarks of cardiovascular ageing. Nat Rev Cardiol. 2023;20:754–777. https://doi.org/ 10.1038/s41569-023-00881-3 - DOI - PubMed
-
- Zhao Y, Liu YS.. Longevity factor FOXO3: a key regulator in aging-related vascular diseases. Front Cardiovasc Med. 2021;8:778674. https://doi.org/ 10.3389/fcvm.2021.778674 - DOI - PMC - PubMed
-
- Chen R, Morris BJ, Donlon TA, et al. FOXO3 longevity genotype mitigates the increased mortality risk in men with a cardiometabolic disease. Aging (Milano). 2020;12:23509–23524. https://doi.org/ 10.18632/aging.202175 - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
